Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 39.71B | 58x | -1.46 | CHF 549 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.3% Upside | Upgrade to Pro+ | |
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 39.71B | 58x | -1.46 | CHF 549 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.3% Upside | Upgrade to Pro+ | |
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 5.26B | 46.1x | 3.12 | CHF 69.80 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.8% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 2.04B | 16.2x | 0.12 | CHF 37.10 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.02B | -89x | -3.26 | CHF 27 | 8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 527.27M | -803.7x | 8.24 | CHF 43.20 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 196.34M | -3.1x | -0.45 | CHF 5.39 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 180.77M | -0.6x | 0.07 | CHF 0.96 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ | |
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 142.97M | 11.8x | 0.4 | CHF 23.90 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 77M | -1.6x | -0.03 | CHF 6.08 | 6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 7.96M | 1.7x | -0.01 | CHF 0.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |